



IN THE UNITED STATES PATENT & TRADEMARK OFFICE  
RESPONSE/AMENDMENT

1615

Case Docket No. 7247M

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an RESPONSE/AMENDMENT for the patent application:

Inventor(s): DOUGLAS J. DOBROZSI

Serial No.: 09/361,542

Group Art Unit: 1615

Date Filed: July 27, 1999

Examiner: A. Pulliam

Title: ORAL LIQUID MUCOADHESIVE COMPOSITIONS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,  
on November 28, 2000

Betty J. Zea

Name of Person Depositing Correspondence

Signature of Person Depositing Correspondence

1. ☐ No additional fee is known to be required.
2. ☐ The fee has been calculated as shown below:

OTHER THAN A  
SMALL ENTITY

	(Col. 1)		(Col. 2)	(Col. 3)		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA*	RATE	FEE
TOTAL	*	MINUS	**	=	x \$22 =	\$
INDEP.	*	MINUS	***	=	x \$78 =	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$250 =	\$
					TOTAL	\$

RECEIVED

DEC 0 6 2000

TECH CENTER 1600/290

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the highest number of total claims previously paid for is less than 20, write "20" in this space.

\*\*\* If the highest number of independent claims previously paid for is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

3. ☐ The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated in the above-identified application to preserve pendency of said application. The processing fee under 37 CFR §1.17 has been determined as follows: \$ for a extension of time.
4. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
  - a. ☒ Any patent application processing fees under 37 CFR §1.16.
  - b. ☒ Any patent application processing fees under 37 CFR §1.17.
5. The Commissioner is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

Betty J. Zea  
Betty J. Zea  
Attorney for Applicant  
Registration No. 36,069  
Tel. No. (513) 622-3952

November 28, 2000  
The Procter & Gamble Company  
Health Care Research Center (Box 1050)  
P.O. Box 8006  
Mason, Ohio 45040-8006  
7247Mtx



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on November 28, 2000.

Andrew Winslow  
Name of Attorney

Betty J. Zea

Betty J. Zea  
Signature of Attorney

RECEIVED

DEC 06 2000

TECH CENTER 1600/2300

P&G Case 7247M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :  
DOUGLAS J. DOBROZSI :  
Serial No. 09/361,542 : Group Art Unit 1615  
Filed July 27, 1999 : Examiner A. Pulliam  
For: Oral Liquid Mucoadhesive Compositions

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action of September 8, 2000, please consider the following remarks. The Commissioner is authorized to enter the following amendments and charge any necessary fees to Deposit Account No. 16-2480. Applicant, however, believes that no fee is due.

IN THE CLAIMS

Please cancel Claims 13-23, 25, 27 and 29.

Please amend the following claim:

Claim 1 (amended). A [per oral or oral,] mucoretentive, aqueous liquid, pharmaceutical composition in oral dosage form comprising:

- (a) from about 2% to about 50%, by weight of the composition, of colloidal particles of silica;
- (b) a safe and effective amount of a pharmaceutical active selected from the group consisting of gastrointestinal agents, analgesics, decongestants, expectorants,